Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.81 USD
−29.22 M USD
0.00 USD
14.60 M
About Calidi Biotherapeutics, Inc.
Sector
Industry
CEO
Allan J. Camaisa
Website
Headquarters
San Diego
Founded
2014
FIGI
BBG012QFCL84
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CLDI is 2.12 USD — it has increased by 10.88% in the past 24 hours. Watch Calidi Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Calidi Biotherapeutics, Inc. stocks are traded under the ticker CLDI.
CLDI stock has fallen by −10.08% compared to the previous week, the month change is a 92.79% rise, over the last year Calidi Biotherapeutics, Inc. has showed a −88.22% decrease.
We've gathered analysts' opinions on Calidi Biotherapeutics, Inc. future price: according to them, CLDI price has a max estimate of 10.00 USD and a min estimate of 2.50 USD. Watch CLDI chart and read a more detailed Calidi Biotherapeutics, Inc. stock forecast: see what analysts think of Calidi Biotherapeutics, Inc. and suggest that you do with its stocks.
CLDI reached its all-time high on Aug 28, 2023 with the price of 137.90 USD, and its all-time low was 0.73 USD and was reached on Oct 25, 2024. View more price dynamics on CLDI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CLDI stock is 10.95% volatile and has beta coefficient of 0.76. Track Calidi Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Calidi Biotherapeutics, Inc. there?
Today Calidi Biotherapeutics, Inc. has the market capitalization of 37.48 M, it has decreased by −1.83% over the last week.
Yes, you can track Calidi Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Calidi Biotherapeutics, Inc. is going to release the next earnings report on Mar 14, 2025. Keep track of upcoming events with our Earnings Calendar.
CLDI earnings for the last quarter are −0.65 USD per share, whereas the estimation was −0.86 USD resulting in a 24.02% surprise. The estimated earnings for the next quarter are −0.37 USD per share. See more details about Calidi Biotherapeutics, Inc. earnings.
CLDI net income for the last quarter is −5.05 M USD, while the quarter before that showed −5.77 M USD of net income which accounts for 12.36% change. Track more Calidi Biotherapeutics, Inc. financial stats to get the full picture.
No, CLDI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 30, 2024, the company has 41.00 employees. See our rating of the largest employees — is Calidi Biotherapeutics, Inc. on this list?
Like other stocks, CLDI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Calidi Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Calidi Biotherapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Calidi Biotherapeutics, Inc. stock shows the sell signal. See more of Calidi Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.